Who is buying NovaBridge Biosciences (NBP)?
As of 20 November 2026: Insiders bought $647k on the open market (2 buys of $50k or more); the latest was Hagler Mark Arnold (Chief Commercial Officer), $70k, filed 2026-11-19. ETFs reported 0 buys or adds and 2 trims or sales since their previous reports (net +$0k).
Insider buys, 12 months$647k
Insider buys
| Filed | Who | Role | Amount | Price |
|---|---|---|---|---|
| 2026-11-19 | Hagler Mark Arnold | Chief Commercial Officer | $70k | $0.38 |
| 2026-04-28 | Hagler Mark Arnold | insider | $577k | $2.51 |
ETF changes
| ETF | Change | Value | Report |
|---|---|---|---|
| State Street(R) Spdr(R) S&p(R) Emerging Markets Small Cap ETF | TRIM | −$0k | 2026-06-30 |
| State Street(R) Spdr(R) S&p(R) China ETF | TRIM | −$0k | 2026-06-30 |
NovaBridge Biosciences: questions and answers
Are insiders buying NBP?
Yes: 2 open-market buys of $50k or more in the last 12 months, $647k in total. The latest was filed 2026-11-19.